These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

523 related items for PubMed ID: 26167726

  • 1. Treatment Outcomes With Rituximab in 100 Patients With Neuromyelitis Optica: Influence of FCGR3A Polymorphisms on the Therapeutic Response to Rituximab.
    Kim SH, Jeong IH, Hyun JW, Joung A, Jo HJ, Hwang SH, Yun S, Joo J, Kim HJ.
    JAMA Neurol; 2015 Sep; 72(9):989-95. PubMed ID: 26167726
    [Abstract] [Full Text] [Related]

  • 2. A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder.
    Kim SH, Huh SY, Lee SJ, Joung A, Kim HJ.
    JAMA Neurol; 2013 Sep 01; 70(9):1110-7. PubMed ID: 23897062
    [Abstract] [Full Text] [Related]

  • 3. Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years.
    Kim SH, Kim W, Li XF, Jung IJ, Kim HJ.
    Arch Neurol; 2011 Nov 01; 68(11):1412-20. PubMed ID: 21747007
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial.
    Nikoo Z, Badihian S, Shaygannejad V, Asgari N, Ashtari F.
    J Neurol; 2017 Sep 01; 264(9):2003-2009. PubMed ID: 28831548
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders with rituximab using a maintenance treatment regimen and close CD19 B cell monitoring. A six-year follow-up.
    Evangelopoulos ME, Andreadou E, Koutsis G, Koutoulidis V, Anagnostouli M, Katsika P, Evangelopoulos DS, Evdokimidis I, Kilidireas C.
    J Neurol Sci; 2017 Jan 15; 372():92-96. PubMed ID: 28017256
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder.
    Huh SY, Kim SH, Hyun JW, Joung AR, Park MS, Kim BJ, Kim HJ.
    JAMA Neurol; 2014 Nov 15; 71(11):1372-8. PubMed ID: 25199960
    [Abstract] [Full Text] [Related]

  • 10. Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder.
    Yang Y, Wang CJ, Wang BJ, Zeng ZL, Guo SG.
    J Neurol Sci; 2018 Feb 15; 385():192-197. PubMed ID: 29406904
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Impact of Rituximab on relapse rate and disability in an Ecuadorian cohort of patients with neuromyelitis optica spectrum disorders.
    Correa-Díaz EP, Torres-Herrán GE, Miño Zambrano JE, Paredes-Gonzalez V, Caiza-Zambrano FJ.
    Mult Scler Relat Disord; 2021 Feb 15; 48():102683. PubMed ID: 33338945
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Rituximab Therapy in Neuromyelitis Optica: Moving Toward a Personalized Medicine Approach.
    Tobin WO, Pittock SJ.
    JAMA Neurol; 2015 Sep 15; 72(9):974-7. PubMed ID: 26168370
    [No Abstract] [Full Text] [Related]

  • 20. Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response.
    Stellmann JP, Krumbholz M, Friede T, Gahlen A, Borisow N, Fischer K, Hellwig K, Pache F, Ruprecht K, Havla J, Kümpfel T, Aktas O, Hartung HP, Ringelstein M, Geis C, Kleinschnitz C, Berthele A, Hemmer B, Angstwurm K, Young KL, Schuster S, Stangel M, Lauda F, Tumani H, Mayer C, Zeltner L, Ziemann U, Linker RA, Schwab M, Marziniak M, Then Bergh F, Hofstadt-van Oy U, Neuhaus O, Zettl U, Faiss J, Wildemann B, Paul F, Jarius S, Trebst C, Kleiter I, NEMOS (Neuromyelitis Optica Study Group).
    J Neurol Neurosurg Psychiatry; 2017 Aug 15; 88(8):639-647. PubMed ID: 28572277
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.